Success Stories: A Chinese Research Associate in the Field of Molecular Biology Retains NAILG after EB-1A Case Approval and Gets NIW Approved Too

Client’s Testimonial:

“Thank you so much for all your effort. I really appreciate it.”

On April 9^th, 2021 and August 4^th, 2021, we received another EB-1A (Alien of Extraordinary Ability) and EB-2 NIW (National Interest Waiver) approval for a Research Associate in the Field of Molecular Biology (Approval Notice).

General Field: Molecular Biology

Position at the Time of Case Filing: Research Associate

Country of Origin: China

State of Residence at the Time of Filing: Pennsylvania

Approval Notice Date: April 9^th, 2021 (EB-1A) and August 4^th, 2021 (NIW)

Processing Time: 2 months, 11 days (EB-1A) (Premium Processing Requested) and 10 months, 21 days (NIW)

Case Summary:

We had already established an attorney-client relationship, when our client, a research associate in molecular biology, wanted to retain us for filing his I-140 NIW (National Interest Waiver) application. Having initially worked with her on her EB-1A (Alien of Extraordinary Ability) case, we had detailed information of her academic and professional records, which we updated with recent achievements. We then made use of this information to ascertain the success of her application at USCIS.

We had known that her research has been supported by funding from a leading agency, demonstrating the recognized value and importance of her work. This funding includes grants from the National Natural Science Foundation of China, which supports basic research, fosters talented researchers, and promotes socio-economic development by implementing a merit-based review system. This grant is reserved for research directly addressing critical problems in molecular biology and the larger society. This funding, therefore, demonstrated the significance and national importance of her research.

We had knowledge that she had built an impressive record of publication. As evidence of her contributions, her work had resulted in 14 peer-reviewed journal articles (2 first-authored and 3 co-first-authored). Moreover, these papers had been published in the top journals in her field, reflecting her peers’ recognition of the value of this research.

She had not only successfully completed and published the results of her research in the field, but her work had also gone on to influence her peers. That is, her publications had been cited a total of 551 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of molecular biology.

In further evidence of her acknowledged expertise in the field, she is also active in the scientific community as a peer reviewer for highly acclaimed journals. She has already conducted at least 15 reviews. Only the foremost experts in their field are invited to perform this important review work, so this frequent review activity further demonstrates her elevated standing in the field.

On the balance, there had been no doubt regarding cancer having a very real, very harmful effect on the United States both as a nation and as a group of individuals. In order to prevent further harm to either people themselves or the nation’s well-being, it was necessary to incorporate experts and research that combat cancer by illuminating cancer’s mechanisms and our client was one such researcher. This argument aided us in corroborating the earlier data and making a convincing case for her.

We at North America Immigration Law Group are grateful to her for showing continued trust in our abilities and allowing us to help her in the process.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.